US OptionsDetailed Quotes
XBIT241220P7500
- 1.00
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
1.00Open1.00Pre Close0 Volume116 Open Interest7.50Strike Price0.00Turnover80.88%IV4.83%PremiumDec 20, 2024Expiry Date0.67Intrinsic Value100Multiplier27DDays to Expiry0.33Extrinsic Value100Contract SizeAmericanOptions Type-0.6209Delta0.2565Gamma6.83Leverage Ratio-0.0102Theta-0.0033Rho-4.24Eff Leverage0.0070Vega
XBiotech Stock Discussion
XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comp...
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in signif...
Where can check this information?
If I have 10 share....
Where is the money? 🧐
No comment yet